[go: up one dir, main page]

MX2024001690A - Composiciones farmacéuticas que comprenden proteínas de fusión de antígeno leucocitario de humano (hla). - Google Patents

Composiciones farmacéuticas que comprenden proteínas de fusión de antígeno leucocitario de humano (hla).

Info

Publication number
MX2024001690A
MX2024001690A MX2024001690A MX2024001690A MX2024001690A MX 2024001690 A MX2024001690 A MX 2024001690A MX 2024001690 A MX2024001690 A MX 2024001690A MX 2024001690 A MX2024001690 A MX 2024001690A MX 2024001690 A MX2024001690 A MX 2024001690A
Authority
MX
Mexico
Prior art keywords
fusion proteins
hla
pharmaceutical compositions
human leukocyte
leukocyte antigen
Prior art date
Application number
MX2024001690A
Other languages
English (en)
Inventor
Anil Kumar
Belaunzaran Osiris Marroquin
Anahita Rafiei
Christoph Renner
Original Assignee
Immunos Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21190004.8A external-priority patent/EP4129323A1/en
Priority claimed from EP21190005.5A external-priority patent/EP4130029A1/en
Application filed by Immunos Therapeutics Ag filed Critical Immunos Therapeutics Ag
Publication of MX2024001690A publication Critical patent/MX2024001690A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden proteínas de fusión de HLA para ser utilizadas para tratar enfermedad neoplásica. La invención también provee medicamentos de combinación que comprenden tanto proteínas de fusión de HLA como inhibidores de punto de control, para ser utilizados para tratar cáncer.
MX2024001690A 2021-08-05 2022-08-05 Composiciones farmacéuticas que comprenden proteínas de fusión de antígeno leucocitario de humano (hla). MX2024001690A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21190004.8A EP4129323A1 (en) 2021-08-05 2021-08-05 A modified hla-b57 with increased expression levels
EP21190005.5A EP4130029A1 (en) 2021-08-05 2021-08-05 Pharmaceutical compositions comprising hla fusion proteins
EP21207324 2021-11-09
PCT/EP2022/072130 WO2023012347A1 (en) 2021-08-05 2022-08-05 Pharmaceutical compositions comprising hla fusion proteins

Publications (1)

Publication Number Publication Date
MX2024001690A true MX2024001690A (es) 2024-04-19

Family

ID=83115511

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2024001690A MX2024001690A (es) 2021-08-05 2022-08-05 Composiciones farmacéuticas que comprenden proteínas de fusión de antígeno leucocitario de humano (hla).
MX2024001689A MX2024001689A (es) 2021-08-05 2022-08-05 Un hla-b57 modificado que tiene niveles de expresion incrementados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024001689A MX2024001689A (es) 2021-08-05 2022-08-05 Un hla-b57 modificado que tiene niveles de expresion incrementados.

Country Status (11)

Country Link
US (2) US20240366718A1 (es)
EP (2) EP4380968B1 (es)
JP (2) JP2024529079A (es)
KR (2) KR20240042017A (es)
AU (2) AU2022324711A1 (es)
BR (2) BR112024002198A2 (es)
CA (2) CA3227299A1 (es)
ES (2) ES3048791T3 (es)
IL (2) IL310615A (es)
MX (2) MX2024001690A (es)
WO (2) WO2023012347A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
CN103459415B (zh) 2010-11-26 2021-04-09 分子组合公司 设计的与血清白蛋白结合的重复蛋白
BR112014032316A2 (pt) 2012-06-28 2017-06-27 Molecular Partners Ag proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
EP3253407B1 (en) 2015-02-04 2020-04-22 Universität Zürich Use of hla-b27 homodimers for cancer treatment
WO2017153438A1 (en) 2016-03-08 2017-09-14 Universität Zürich Hla-b57 open conformers
CA3031605A1 (en) 2016-08-10 2018-02-15 Universitat Zurich Mhc class ia open conformers
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段

Also Published As

Publication number Publication date
KR20240042017A (ko) 2024-04-01
ES3048791T3 (en) 2025-12-11
KR20240045259A (ko) 2024-04-05
MX2024001689A (es) 2024-04-19
EP4380968A1 (en) 2024-06-12
AU2022324711A1 (en) 2024-02-01
CA3227284A1 (en) 2023-02-09
JP2024530199A (ja) 2024-08-16
WO2023012347A1 (en) 2023-02-09
BR112024002196A2 (pt) 2024-04-30
US20240269232A1 (en) 2024-08-15
BR112024002198A2 (pt) 2024-04-30
JP2024529079A (ja) 2024-08-01
WO2023012348A1 (en) 2023-02-09
EP4380595B1 (en) 2025-10-01
EP4380968C0 (en) 2025-10-01
US20240366718A1 (en) 2024-11-07
AU2022323540A1 (en) 2024-02-15
ES3048639T3 (en) 2025-12-11
EP4380595C0 (en) 2025-10-01
IL310612A (en) 2024-04-01
IL310615A (en) 2024-04-01
CA3227299A1 (en) 2023-02-09
EP4380595A1 (en) 2024-06-12
EP4380968B1 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
CY1125429T1 (el) Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
PH12023550266A1 (en) Anti-ceacam5 antibodies and conjugates and uses thereof
CU20170169A7 (es) Anticuerpos de factor xi
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
BRPI0622073A8 (pt) Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
SA523440623B1 (ar) أجسام مضادة
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
DOP2013000218A (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
CO2023001559A2 (es) Anticuerpos fgfr3 y métodos de uso
BR112022021447A2 (pt) Moléculas de ligação para o tratamento de câncer
AR115257A1 (es) Anticuerpos de fijación a bcma y sus usos
BR112018068135A2 (pt) conformador aberto de hla-b57
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
BR112019009029A2 (pt) anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico
BR112019011350A2 (pt) terapia de combinação
BR112022002236A2 (pt) Composições, composições farmacêuticas e uso das mesmas para tratar câncer, bem como formulações que compreendem as mesmas
MX2024001690A (es) Composiciones farmacéuticas que comprenden proteínas de fusión de antígeno leucocitario de humano (hla).
DOP2025000170A (es) Proteínas de fusión fc de il-12
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp